Sarborg

Sarborg Limited is a technology company founded in 2024 that develops predictive tools for the pharmaceutical industry through artificial intelligence, cybernetics, and machine learning. The company's core focus is on drug repurposing, where it uses proprietary AI agents and algorithms to match unique drug and disease signatures. This approach enables pharmaceutical companies to optimize their asset portfolios, shorten discovery timelines, and improve the success rates of clinical trials.

The company's business model includes providing services to pharmaceutical clients and developing its own internal pipeline of pharmaceutical assets for future monetization through out-licensing or royalty-based deals. Sarborg has already secured an initial services agreement with a NASDAQ-listed pharmaceutical company, for which it delivered personalized dashboards for real-time data access and R&D oversight. In a partnership with Conduit Pharmaceuticals, Sarborg is applying its AI and cybernetics platform to optimize processes like drug discovery, clinical trial monitoring, and solid-form identification.

In August 2025, Sarborg announced the closing of a $10 million Seed funding round led by Corvus Capital. The capital is intended to scale its AI-driven drug development, expand its intellectual property portfolio, and diversify into other analytical fields beyond the pharmaceutical sector. The company has built a proprietary portfolio of over 800 disease signatures mapped with its data-driven approach. Sarborg Limited is registered in the Cayman Islands and has an office in Wilmington, Delaware.

Keywords: drug repurposing, artificial intelligence, machine learning, cybernetics, pharmaceutical innovation, clinical trial optimization, predictive intelligence, drug discovery, asset portfolio management, disease signatures, HealthTech, Big Data, computational cybernetics, AI agents, drug development, indication selection, clinical trial monitoring, solid-form identification, bioinformatics, personalized medicine